Tag

economy

Browsing

by Bill Sardi

While Wall Street awaits the entry of over 1,813 new cancer drugs into human clinical trials representing billions of dollars of investment capital, the announcement of a bona fide cure for cancer comes from an outsider – patient Joe Tippens.

An astounding report of Mr. Tippens’ cancer cure is circulating the internet now.  First diagnosed with small cell lung cancer in 2016 and with tumors popping up on scans in virtually every organ in his body, in desperation Joe Tippens began using a dog de-worming agent at the suggestion of a veterinarian.

He was told this cancer cure “was batting 1,000 in killing different cancers.”  He heard one of the scientists involved in the research was cured.  He had no time to dither.  He was weeks away from dying.

Treatment began in the third week of January 2017.  Three months later at MD Anderson Cancer Hospital in Houston, Tippens anxiously awaited the report of his oncologist who had no idea Tippens started taking the dog deworming medication.

The doctor is reported to have walked up to Mr. Tippens and said: “I am going to have to ask you to leave this hospital, because we only treat patients with cancer here at MD Anderson.”


Within just 3 months his cancer vanished.  His insurance company spent $1.2 million before Tippens switched to a $5 a week medicine that saved his life.  Daily vitamins and CBD oil were also an essential part of his curative regimen.  Here’s the video report.

Don’t think Big Pharma isn’t involved here.  Merck Animal Health division makes the de-worming drug that has gone up in price since the report of Tippens’ cure spread in the news media.

Joe Tippens now reports at his own “My Cancer Story Rocks” blog site that is bustling with visitors.

He now says around 40 otherwise hopeless cancer patients have reported similar cures.

He continues to take the anti-worming medication and dietary supplements as prevention.

His dietary supplement regimen that he still adheres to is as follows:

  • Vitamin E complex (tocotrienols, tocopherols)
  • Curcumin (turmeric extract 600 mg/day
  • CBD oil

The history of this cure

The anti-tumor therapy involves an anti-worming agent used for horses and dogs. It has been deemed to be safe by the Food & Drug Administration.  Published studies involving this canine drug, fenbendazole, date back a couple of decades.  There has been a lot of foot dragging over fenbendazole since it was unexpectedly reported to exhibit potent anti-cancer properties when combined with a vitamin regimen in laboratory animals in a study published in 2008.

Researchers reported that fenbendazole alone or vitamins alone did not alter the size or growth of implanted tumors in laboratory mice.  But their combination produced a striking increase in activity of one type of white blood cell, neutrophils, resulting in a no-growth effect.  There also was strong inhibition of a protein (hypoxia inducing factor) that induces hypoxia (absence of oxygen) which forces cancer cells to utilize sugar for energy rather than oxygen.

In the laboratory this drug/vitamin combo overcame treatment resistance as well.

Researchers were initially investigating fenbendazole because it was interfering with anti-tumor studies with other drugs.

Given that pinworms are a common problem in laboratories where mice are employed in pre-clinical testing of anti-cancer drugs, use of fenbendazole to clear these animals of parasites is standard practice.

Unexpectedly, fenbendazole halted the growth of implanted human lymphoma cells in rodents.

To prevent animal infection during the testing period the chow fed to these lab animals is sterilized and then vitamins and minerals (vitamin A, D, E, K and B) are added back to eliminate variance in nutrient intake.  But the chow for these lab animals in question was not sterilized and therefore more nutrients were delivered to these animals than normal.

Whereas implanted tumors take hold and grow 80-100% of the time, in this experiment none of the implanted tumors grew among 40 animals over a 30-day period!  This was striking.

In 2011 researchers investigated fenbendazole for its ability to treat a nasty form of brain cancer (glioblastoma multiforme).  Five-year survival with this form of brain cancer is only 10%. Over 600 clinical trials for this form of cancer have been unsuccessful in finding a cure.  These researchers found the addition of an anti-worming (pinworm) agent (fenbendazole) halted the growth of brain tumors whereas among animals that were not de-wormed, there was consistent tumor growth.  The researchers noted the long track record of safety for fenbendazole as well as its low cost and availability.

Contrarily, in 2013 researchers reported they found no evidence that fenbendazole has value in cancer therapy and did not warrant further testing.

Then in 2018 researchers in India reported fenbendazole exerts cancer cell killing activity at very low concentrations and does so partially by its inherent ability to inhibit the uptake of sugar (glucose) into fast-growing tumor cells.  Cancer cells develop an inordinate demand for sugar to feed their growth, switching from oxygen to sugar as a source of energy.  Fenbendazole did this by inhibition of an enzyme called hexokinase.

Fenbendazole’s ability to preferentially kill of malignant cells without harming healthy cells is another of its proposed properties.

The last thing the cancer industry needs is a cure

The last thing the cancer industry needs is a cure.  In fact, it can’t afford a cure.

Financial analysts admit “a cancer cure is not a sustainable business model.”

Read the Whole Article

Do you find these posts helpful and informative? Please CLICK HERE to help keep us going!

By John Devanny

“The revenue of the state is the state.”  Edmund Burke, Reflections on the French Revolution

Washington D. C. finds itself in the midst of an entertaining, nay consuming, Kabuki theatre.  The federal government has “shut down” its non-essential functions, re-opened the same, and promised to do it all over again in a few weeks, raising the question as to why it has non-essential functions at all.  Mr. Mueller’s fishing expedition continues sailing along through Mr. Trump’s tweetstorms, as Democrats await the landing of the big tuna complete with waterside fish fry and impeachment. Meanwhile, the Trumpites patiently fantasize about their man turning the tables on the evil deep state by purging the temples and draining good ol’ foggy bottom.  T’is all sound and fury underscoring Henry Kissinger’s view that the smaller the stakes, the more vicious the politics.

What is currently at stake is the survival of the last vestiges, really the tatters and shreds, of the old republic, and no one, neither leftists identity politics ideologues or MAGA hat wearing Trumpites are lifting even a whimper of protest, minus a few notable exceptions such as journalist Greg Hunter.  What matters is 21 trillion dollars of unaccounted for spending.  The story takes us back to the eve of the 9/11 attacks.  Donald Rumsfeld, the Secretary of Defense, disclosed a particularly embarrassing piece of news that the Defense Department spent 2.3 trillion dollars and could not account for it.  Conveniently for Rumsfeld and the DoD, some folks decided to pilot passenger jetliners into the World Trade Center’s twin towers, so the issue of the “missing money”  fell to the wayside.  Until, Catherine Austin Fitts, a former Assistant Secretary of Housing during Daddy Bush’s reign, claimed that around 6 trillion dollars of spending could not be accounted for in the Department of Housing and Urban Development budget.  One Dr. Mark Skidmore, a professor of economics and the holder of the Morris Chair of State and Local Government Finance and Policy at Michigan State University, was sure Fitts and her researchers were incorrect.  So he and a team of graduate students combed through the publicly available financial records and found that Fitts was correct.  So, just for kicks, they took a look at the spending records of the DoD and found another 15 trillion of unaccounted spending.  As Skidmore and his intrepid team dug deeper into the bowels of federal agencies with information requests, the Office of the Inspector General pulled the plug on all the internet links to the key documents that showed the unaccounted for spending.  Eventually, the links came back up, and with a promise of an audit of spending by the DoD.  Clearly, Dr. Skidmore had hit a nerve.

Various and sundry debunkers have gone into overdrive to assure us that all is well.  The leading court newspaper, the Washington Post, is quite certain that this is a case of double counting or perhaps lost receipts.  Other sober-minded folks have compared this to someone forgetting about the twenty-five bucks you paid an enterprising teenager to mow your lawn, or perhaps it’s like when you forget to report a meal on your expense account, or you double booked the latte at Starbucks.  A few lawns, some lattes, some double booked F-35s, some uncounted $300.00 toilet seats and pretty soon we have 21 trillion dollars of unaccounted spending.  The Post never produced any evidence of plugging or double booking of accounts, bless their hearts, they just took the federal government at its word.

But we really can’t take the federal government at its word.  Consider Federal Accounting Standards Advisory Board (FASAB) Statement 56.  According to Michele Ferri and Jonathan Luire, Statement 56 is fraught with perils for the republic.

In the absolute most simple terms, Standard 56 allows federal entities to shift amounts from line item to line item and sometimes even omit spending altogether when reporting their financials in order to avoid the potential of revealing classified information.1 However, as with all laws, nearly every word in that sentence is a complicated concept to unpack. Who counts as a federal reporting entity? When and how can these entities conceal or remove financial information from their reports? What information can be removed? When does something count as confidential, and who makes that determination? . . .

The simplest place to start with understanding Standard 56 is its scope. It applies to federal entities that issue unclassified general purpose federal financial reports (GPFFR), including where one entity is consolidated with another. This means it only applies to otherwise unclassified financial reports where there is a risk of revealing classified information; classified financial reports are their own can of worms. (see generally FASAB Statement of Federal Financial Accounting Standards 56, available at http://files.fasab.gov/pdffiles/handbook_sffas_56.pdf) Standard 56 also doesn’t remove the actual requirement to report, it just allows these entities to change their reports in ways that don’t reflect their actual spending.

Simply put, a broad interpretation of Statement 56 (When has the federal government not chosen the broad interpretation?), books can be cooked if an entity, public or private, is spending money or fiscally involved in operations that are related to national security.  This renders the balance sheets and accounts of both the federal government and the corporations that do business with the government, deeply suspect at best, completely untrustworthy at worst.  Most ominous, it effectively removes public spending from any meaningful oversight by the people or the representatives of the people and the states in the Congress.  What is in place now is the legal architecture to support legitimize financial fraud.

Read the Whole Article

Do you find these posts helpful and informative? Please CLICK HERE to help keep us going!